ALK and non-small cell lung carcinoma: However, patients harboring the L1198F mutation, which confers resistance to lorlatinib, have reported re-sensitivity to crizotinib.30 This result indicates that retreatment under molecular guidance should be considered as a clinically meaningful approach for ALK-positive NSCLC.